According to a recent LinkedIn post from Orbis Medicines, the company is positioning itself around the growing field of oral biologics, citing Johnson & Johnson’s recent FDA approval of Icotyde as a key inflection point. The post references comments from CEO Morten Graugaard in Pharmaceutical Executive, where he reportedly discussed how this approval may signal broader acceptance of macrocycle IL-23 receptor antagonists and related modalities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights both the momentum and remaining hurdles for oral biologics, including challenges such as bioavailability and scalable manufacturing, as well as competition with entrenched injectable therapies. It also presents Orbis’s nGen platform as an attempt to systematize macrocycle drug discovery into a more programmable, data-driven process, rather than a low-throughput, artisanal approach.
For investors, the post suggests that Orbis is aligning its strategy with a potentially expanding market segment in drug development, where successful oral biologics could command premium pricing and wider patient adoption. If the nGen platform can materially improve discovery efficiency and success rates in orally bioavailable macrocycles, it could enhance Orbis’s ability to attract partnerships, licensing deals, or later-stage financing.
At the industry level, the emphasis on competing with injectable therapies points to possible long-term shifts in treatment paradigms, particularly in chronic immune and inflammatory conditions where IL-23 targets are relevant. While the post does not reference specific pipeline assets, timelines, or clinical data from Orbis, it frames the company as an early participant in a technology trend that larger pharma players are beginning to validate through regulatory approvals.